Cover Image
市場調查報告書

帕金森氏症:開發中產品分析

Parkinson's Disease - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 229809
出版日期 內容資訊 英文 833 Pages
訂單完成後即時交付
價格
Back to Top
帕金森氏症:開發中產品分析 Parkinson's Disease - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 833 Pages
簡介

帕金森氏症,是有運動功能障礙特徵的神經退化性疾病,靜下時顫抖,肌肉僵硬,運動器官的功能障礙。原因有年齡、遺傳要素、頭部外傷、環境要素、荷爾蒙的變化等。 帕金森氏症造成神經原功能異常,也可能導致神經原死亡。神經原,擔負著信號傳達原的神經傳達物質多巴胺的合成,神經原受到影響阻礙神經有效的傳達,使運動功能和肌肉的調整力下降。

本報告提供帕金森氏症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

帕金森氏症概要

治療藥的開發

帕金森氏症:企業開發中的治療藥

帕金森氏症:大學/機關研究中的治療藥

帕金森氏症:開發中產品概況

帕金森氏症:企業開發中的產品

帕金森氏症:大學/機關研究中的產品

帕金森氏症的治療藥開發作的企業

帕金森氏症:治療藥的評估

藥物簡介

帕金森氏症:暫停中的計劃

帕金森氏症:開發中止的產品

帕金森氏症:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7961IDB

Summary

Global Markets Direct's, 'Parkinson's Disease - Pipeline Review, H1 2016', provides an overview of the Parkinson's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Parkinson's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Parkinson's Disease
  • The report reviews pipeline therapeutics for Parkinson's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Parkinson's Disease therapeutics and enlists all their major and minor projects
  • The report assesses Parkinson's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Parkinson's Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Parkinson's Disease Overview
  • Therapeutics Development
  • Parkinson's Disease - Therapeutics under Development by Companies
  • Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes
  • Parkinson's Disease - Pipeline Products Glance
  • Parkinson's Disease - Products under Development by Companies
  • Parkinson's Disease - Products under Investigation by Universities/Institutes
  • Parkinson's Disease - Companies Involved in Therapeutics Development
  • Parkinson's Disease - Therapeutics Assessment
  • Drug Profiles
  • Parkinson's Disease - Dormant Projects
  • Parkinson's Disease - Discontinued Products
  • Parkinson's Disease - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Parkinson's Disease, H1 2016
  • Number of Products under Development for Parkinson's Disease - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Parkinson's Disease - Pipeline by AC Immune SA, H1 2016
  • Parkinson's Disease - Pipeline by Acelot, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Acorda Therapeutics, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd, H1 2016
  • Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016
  • Parkinson's Disease - Pipeline by AFFiRiS AG, H1 2016
  • Parkinson's Disease - Pipeline by Alexza Pharmaceuticals, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Amabiotics SAS, H1 2016
  • Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016
  • Parkinson's Disease - Pipeline by American Gene Technologies International Inc., H1 2016
  • Parkinson's Disease - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Parkinson's Disease - Pipeline by Angita B.V., H1 2016
  • Parkinson's Disease - Pipeline by Antoxis Limited, H1 2016
  • Parkinson's Disease - Pipeline by APeT Holding BV, H1 2016
  • Parkinson's Disease - Pipeline by ApoPharma Inc., H1 2016
  • Parkinson's Disease - Pipeline by Aposense Ltd., H1 2016
  • Parkinson's Disease - Pipeline by Araclon Biotech, S.L., H1 2016
  • Parkinson's Disease - Pipeline by ArmaGen Inc., H1 2016
  • Parkinson's Disease - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
  • Parkinson's Disease - Pipeline by AstraZeneca Plc, H1 2016
  • Parkinson's Disease - Pipeline by Berg LLC, H1 2016
  • Parkinson's Disease - Pipeline by Bial - Portela & Ca, S.A., H1 2016
  • Parkinson's Disease - Pipeline by Bio-Modeling Systems SAS, H1 2016
  • Parkinson's Disease - Pipeline by BioArctic Neuroscience AB, H1 2016
  • Parkinson's Disease - Pipeline by Biogen, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Bionature E.A. Ltd., H1 2016
  • Parkinson's Disease - Pipeline by Biopharm GmbH, H1 2016
  • Parkinson's Disease - Pipeline by Biotie Therapies Corp., H1 2016
  • Parkinson's Disease - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2016
  • Parkinson's Disease - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Calico LLC, H1 2016
  • Parkinson's Disease - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Carna Biosciences, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Cell Cure Neurosciences, Ltd., H1 2016
  • Parkinson's Disease - Pipeline by Cellceutix Corporation, H1 2016
  • Parkinson's Disease - Pipeline by CHA Bio & Diostech Co., Ltd., H1 2016
  • Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Parkinson's Disease - Pipeline by Clera Inc., H1 2016
  • Parkinson's Disease - Pipeline by Clevexel Pharma SAS, H1 2016
  • Parkinson's Disease - Pipeline by Contera Pharma ApS, H1 2016
  • Parkinson's Disease - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Corium International, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Curemark, LLC, H1 2016
  • Parkinson's Disease - Pipeline by Cynapsus Therapeutics Inc., H1 2016
  • Parkinson's Disease - Pipeline by D-Pharm Ltd., H1 2016
  • Parkinson's Disease - Pipeline by Depomed, Inc., H1 2016
  • Parkinson's Disease - Pipeline by DermaXon, LLC, H1 2016
  • Parkinson's Disease - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016
  • Parkinson's Disease - Pipeline by Dizlin Medical Design AB, H1 2016
  • Parkinson's Disease - Pipeline by Domain Therapeutics SA, H1 2016
  • Parkinson's Disease - Pipeline by Edison Pharmaceuticals, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Eli Lilly and Company, H1 2016
  • Parkinson's Disease - Pipeline by Ensemble Therapeutics Corporation, H1 2016
  • Parkinson's Disease - Pipeline by Euroscreen S.A., H1 2016
  • Parkinson's Disease - Pipeline by FPRT Bio Inc., H1 2016
  • Parkinson's Disease - Pipeline by Gene Solutions LLC, H1 2016
  • Parkinson's Disease - Pipeline by Genecode AS, H1 2016
  • Parkinson's Disease - Pipeline by Genentech, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016
  • Parkinson's Disease - Pipeline by GenKyoTex S.A., H1 2016
  • Parkinson's Disease - Pipeline by Genosco, H1 2016
  • Parkinson's Disease - Pipeline by Genzyme Corporation, H1 2016
  • Parkinson's Disease - Pipeline by H. Lundbeck A/S, H1 2016
  • Parkinson's Disease - Pipeline by Harbor Therapeutics, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Heptares Therapeutics Limited, H1 2016
  • Parkinson's Disease - Pipeline by Herantis Pharma Plc, H1 2016
  • Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016
  • Parkinson's Disease - Pipeline by Huons Co., Ltd., H1 2016
  • Parkinson's Disease - Pipeline by Immune Design Corp., H1 2016
  • Parkinson's Disease - Pipeline by Immungenetics AG, H1 2016
  • Parkinson's Disease - Pipeline by Impel NeuroPharma, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Intec Pharma ltd., H1 2016
  • Parkinson's Disease - Pipeline by Integrative Research Laboratories Sweden AB, H1 2016
  • Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H1 2016
  • Parkinson's Disease - Pipeline by International Stem Cell Corporation, H1 2016
  • Parkinson's Disease - Pipeline by Intra-Cellular Therapies, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Io Therapeutics, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Iproteos S.L., H1 2016
  • Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
  • Parkinson's Disease - Pipeline by Kainos Medicine, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Khondrion BV, H1 2016
  • Parkinson's Disease - Pipeline by KineMed, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H1 2016
  • Parkinson's Disease - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Living Cell Technologies Limited, H1 2016
  • Parkinson's Disease - Pipeline by Longevity Biotech, Inc, H1 2016
  • Parkinson's Disease - Pipeline by Luye Pharma Group Ltd., H1 2016
  • Parkinson's Disease - Pipeline by M et P Pharma AG, H1 2016
  • Parkinson's Disease - Pipeline by M's Science Corporation, H1 2016
  • Parkinson's Disease - Pipeline by M3 Biotechnology, Inc., H1 2016
  • Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc., H1 2016
  • Parkinson's Disease - Pipeline by Merck & Co., Inc., H1 2016
  • Parkinson's Disease - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016
  • Parkinson's Disease - Pipeline by Metabolic Solutions Development Company, LLC, H1 2016
  • Parkinson's Disease - Pipeline by Minerva Neurosciences, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Mission Therapeutics Limited, H1 2016
  • Parkinson's Disease - Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016
  • Parkinson's Disease - Pipeline by MitoDys Therapeutics Limited, H1 2016
  • Parkinson's Disease - Pipeline by Motac Neuroscience Limited, H1 2016
  • Parkinson's Disease - Pipeline by Netherlands Translational Research Center B.V., H1 2016
  • Parkinson's Disease - Pipeline by Neuralstem, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Limited, H1 2016
  • Parkinson's Disease - Pipeline by NeuroDerm Ltd., H1 2016
  • Parkinson's Disease - Pipeline by Neurodyn Inc., H1 2016
  • Parkinson's Disease - Pipeline by NeuroNascent, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Neuronax SAS, H1 2016
  • Parkinson's Disease - Pipeline by NeurOp, Inc, H1 2016
  • Parkinson's Disease - Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Neuropore Therapies, Inc., H1 2016
  • Parkinson's Disease - Pipeline by New World Laboratories, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Newron Pharmaceuticals S.p.A., H1 2016
  • Parkinson's Disease - Pipeline by nLife Therapeutics, S.L., H1 2016
  • Parkinson's Disease - Pipeline by NLS Pharma Group, H1 2016
  • Parkinson's Disease - Pipeline by Novartis AG, H1 2016
  • Parkinson's Disease - Pipeline by NsGene A/S, H1 2016
  • Parkinson's Disease - Pipeline by Omeros Corporation, H1 2016
  • Parkinson's Disease - Pipeline by Oncodesign SA, H1 2016
  • Parkinson's Disease - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Parkinson's Disease - Pipeline by OPKO Health, Inc., H1 2016
  • Parkinson's Disease - Pipeline by Orion Oyj, H1 2016
  • Parkinson's Disease - Pipeline by Oryzon Genomics S.A., H1 2016
  • Parkinson's Disease - Pipeline by Osmotica Pharmaceutical Corp., H1 2016
  • Parkinson's Disease - Pipeline by Oxford BioMedica Plc, H1 2016

List of Figures

  • Number of Products under Development for Parkinson's Disease, H1 2016
  • Number of Products under Development for Parkinson's Disease - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top